As Allergan continues to fight a hostile takeover by Canadian rival Valeant, reports say Actavis is now seeking a renewed acquisition of the maker of Botox.
Reports emerged last month that Allergan had denied Actavis’s bid for the company, currently valued at about $55 billion. But Actavis is now reporting a renewed effort to take over the company, unnamed sources said Tuesday. The two pharmaceutical firms have held informal merger discussions in recent months, and Allergan is reportedly considering accepting an offer from Actavis if an offer is made at more than $200 per share.
One source said Actavis would reach out as soon as this week to Allergan’s management to emphasize its interest in a takeover.
The reports come as Valeant is said to have revamped its offer for the Botox maker, offering about $190 per share. But Valeant could come out with an even higher offer later this month, reports say.
Full content: Sun-Sentinel
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI